Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9926339 | 1.00 | KIF11 (0.44) | KIF11DNMT1 | |
| SCHEMBL906631 | 0.77 | CTSK (0.48) | KIF11 | |
| SCHEMBL5276867 | 0.77 | CTSK (0.48) | KIF11 | |
| SCHEMBL9926338 | 0.76 | KIF11 (0.47) | KIF11DNMT1 | |
| SCHEMBL7683096 | 0.75 | KIF11 (0.43) | KIF11DNMT1 | |
| SCHEMBL12944846 | 0.75 | KIF11 (0.56) | KIF11DNMT1 | |
| SCHEMBL4410619 | 0.74 | KIF11 (0.56) | KIF11DNMT1 | |
| SCHEMBL20202837 | 0.74 | KIF11 (0.56) | KIF11DNMT1 | |
| SCHEMBL30408374 | 0.74 | KIF11 (0.56) | KIF11DNMT1 | |
| SCHEMBL7837119 | 0.73 | CTSK (0.57) | KIF11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120115783-A1 | PEPTIDOMIMETIC MACROCYCLES | Alleron therapeutics, Inc (US) | 2012-05-10 | — | — | US | disclosed |
| US-7960506-B2 | Bis-sulfhydryl macrocyclization systems | AILERON THERAPEUTICS, INC. (US) | 2011-06-14 | — | — | US | disclosed |
| US-20100216688-A1 | PEPTIDOMIMETIC MACROCYCLES | AILERON THERAPEUTICS, INC. (US) | 2010-08-26 | — | — | US | disclosed |
| US-20090088553-A1 | Bis-Sulfhydryl Macrocyclization Systems | AILERON THERAPEUTICS, INC., A DELAWARE CORPORATION (US) | 2009-04-02 | — | — | US | disclosed |
| US-20090047711-A1 | BIS-SULFHYDRYL MACROCYCLIZATION SYSTEMS | AILERON THERAPEUTICS, INC. (US) | 2009-02-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090088553-A1 | Bis-Sulfhydryl Macrocyclization Systems | CBS, HLCS, CTH | KIF11 3508/4885DNMT1 4260/4885 |
| US-20090047711-A1 | BIS-SULFHYDRYL MACROCYCLIZATION SYSTEMS | CBS, HLCS, CTH | KIF11 3508/4885DNMT1 4260/4885 |
| US-20100216688-A1 | PEPTIDOMIMETIC MACROCYCLES | CCL2, TAP2, TAP1 | KIF11 2655/4885DNMT1 4352/4885 |
| US-20120115783-A1 | PEPTIDOMIMETIC MACROCYCLES | GLP1R, PROKR1, VIP | KIF11 2332/4885DNMT1 4442/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.